09.05.2012 • NewsNovozymesbiopharmaceuticalscGMP

Novozymes Now Supplying Pharmaceutical Grade Q7 cGMP Hyaluronic Acid

Novozymes Biopharma, part of Novozymes, has announced the first shipment of the company's Bacillus-derived hyaluronic acid, Hyasis, from its newly inaugurated manufacturing facility in China, which represents an investment of more than DKK 350 million.

The facility in Tianjin employs a patented water-based process to manufacture Hyasis to Q7 cGMP standards.

The first commercial products using Hyasis as a raw material are expected to reach the market in Q2 of this year.

 

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read